UBS analyst John Sourbeer initiated coverage of 10x Genomics with a Neutral rating and $50 price target. The analyst believes the company is positioned to grow revenue 22% through 2026, inline with consensus, but sees several possible headwinds, including cannibalization of single cell by spatial platforms. 10x is still catching up in spatial and its valuation is above the peer group, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG:
